| Risk Factor . | Overall survival (death at 2 years) . | |||
|---|---|---|---|---|
| Univariate analysis . | Cox regression analysis . | |||
| HR (95% CI) . | P-value . | aHR (95% CI) . | P-value . | |
| Female sex | 0.98 (0.73–1.3) | .92 | - | - |
| Age ≥ 65 | 1.7 (1.2–2.2) | <.001 | 1.5 (1.0–2.2) | .03 |
| KPS ≥ 70 | 0.72 (0.5–0.9) | .04 | 0.6 (0.4–0.9) | .01 |
| BMI (kg/m2) ≥ 25 | 0.84 (0.6–1.2) | .3 | - | - |
| Methylated MGMT | 0.6 (0.4–0.8) | <.001 | 0.5 (0.3–0.7) | <.001 |
| Complete resection | 0.6 (0.4–0.8) | <.001 | 0.7 (0.5–1.0) | .03 |
| Combined adjuvant therapy | 0.3 (0.2–0.4) | <.001 | 0.3 (0.2–0.5) | <.001 |
| Mean positive Δ NLR ≥ 6.0 | 1.8 (1.1–3.0) | .01 | 1.4 (0.8–2.6) | .2 |
| Risk Factor . | Overall survival (death at 2 years) . | |||
|---|---|---|---|---|
| Univariate analysis . | Cox regression analysis . | |||
| HR (95% CI) . | P-value . | aHR (95% CI) . | P-value . | |
| Female sex | 0.98 (0.73–1.3) | .92 | - | - |
| Age ≥ 65 | 1.7 (1.2–2.2) | <.001 | 1.5 (1.0–2.2) | .03 |
| KPS ≥ 70 | 0.72 (0.5–0.9) | .04 | 0.6 (0.4–0.9) | .01 |
| BMI (kg/m2) ≥ 25 | 0.84 (0.6–1.2) | .3 | - | - |
| Methylated MGMT | 0.6 (0.4–0.8) | <.001 | 0.5 (0.3–0.7) | <.001 |
| Complete resection | 0.6 (0.4–0.8) | <.001 | 0.7 (0.5–1.0) | .03 |
| Combined adjuvant therapy | 0.3 (0.2–0.4) | <.001 | 0.3 (0.2–0.5) | <.001 |
| Mean positive Δ NLR ≥ 6.0 | 1.8 (1.1–3.0) | .01 | 1.4 (0.8–2.6) | .2 |
Abbreviations: CI, confidence interval; BMI, body mass index; H, high; HR, hazard ratio; IQR, interquartile range; KPS, Karnofsky Performance Scale; L, low; MGMT, O6-methylguanine-DNA methyltransferase; NLR, neutrophil-to-lymphocyte ratio.
Complete resection denotes near gross total resection and gross total resection. High ΔNLR denotes an average of ≥6. ΔNLR signifies a change in NLR from preoperative to postoperative NLR values = postoperative NLR—preoperative NLR.
| Risk Factor . | Overall survival (death at 2 years) . | |||
|---|---|---|---|---|
| Univariate analysis . | Cox regression analysis . | |||
| HR (95% CI) . | P-value . | aHR (95% CI) . | P-value . | |
| Female sex | 0.98 (0.73–1.3) | .92 | - | - |
| Age ≥ 65 | 1.7 (1.2–2.2) | <.001 | 1.5 (1.0–2.2) | .03 |
| KPS ≥ 70 | 0.72 (0.5–0.9) | .04 | 0.6 (0.4–0.9) | .01 |
| BMI (kg/m2) ≥ 25 | 0.84 (0.6–1.2) | .3 | - | - |
| Methylated MGMT | 0.6 (0.4–0.8) | <.001 | 0.5 (0.3–0.7) | <.001 |
| Complete resection | 0.6 (0.4–0.8) | <.001 | 0.7 (0.5–1.0) | .03 |
| Combined adjuvant therapy | 0.3 (0.2–0.4) | <.001 | 0.3 (0.2–0.5) | <.001 |
| Mean positive Δ NLR ≥ 6.0 | 1.8 (1.1–3.0) | .01 | 1.4 (0.8–2.6) | .2 |
| Risk Factor . | Overall survival (death at 2 years) . | |||
|---|---|---|---|---|
| Univariate analysis . | Cox regression analysis . | |||
| HR (95% CI) . | P-value . | aHR (95% CI) . | P-value . | |
| Female sex | 0.98 (0.73–1.3) | .92 | - | - |
| Age ≥ 65 | 1.7 (1.2–2.2) | <.001 | 1.5 (1.0–2.2) | .03 |
| KPS ≥ 70 | 0.72 (0.5–0.9) | .04 | 0.6 (0.4–0.9) | .01 |
| BMI (kg/m2) ≥ 25 | 0.84 (0.6–1.2) | .3 | - | - |
| Methylated MGMT | 0.6 (0.4–0.8) | <.001 | 0.5 (0.3–0.7) | <.001 |
| Complete resection | 0.6 (0.4–0.8) | <.001 | 0.7 (0.5–1.0) | .03 |
| Combined adjuvant therapy | 0.3 (0.2–0.4) | <.001 | 0.3 (0.2–0.5) | <.001 |
| Mean positive Δ NLR ≥ 6.0 | 1.8 (1.1–3.0) | .01 | 1.4 (0.8–2.6) | .2 |
Abbreviations: CI, confidence interval; BMI, body mass index; H, high; HR, hazard ratio; IQR, interquartile range; KPS, Karnofsky Performance Scale; L, low; MGMT, O6-methylguanine-DNA methyltransferase; NLR, neutrophil-to-lymphocyte ratio.
Complete resection denotes near gross total resection and gross total resection. High ΔNLR denotes an average of ≥6. ΔNLR signifies a change in NLR from preoperative to postoperative NLR values = postoperative NLR—preoperative NLR.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
